RGNX stock news · REGENXBIO Inc.
Get alerts for RGNX
Follow REGENXBIO Inc. (RGNX) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for RGNXREGENXBIO Inc. says some directors and officers are leaving, while new ones are being chosen.
NeutralREGENXBIO’s board chair is changing after Kenneth Mills took another CEO role. The filing reports no company dispute or business change, so this does not change the company’s outlook.
Regenxbio shares details from its earnings call for the second quarter of 2026.
Good for RGNXRegenxbio reported progress in its gene therapy studies and received a large payment from AbbVie. The added cash and completed enrollment point to a stronger outlook.
Sarepta Therapeutics, Inc. has signed an important agreement to settle patent disputes with REGENXBIO, the University of Pennsylvania, and Catalent.
Bad for RGNXREGENXBIO will receive $39.0 million but gave up the right to sue over patents covering the AAVrh74 capsid and the existing form of ELEVIDYS, reducing future enforcement leverage.
Regulatory challenges arise for Regenxbio as FDA places RGX-121 on clinical hold.
NeutralRegenxbio's stock is trading lower following the FDA's decision to place a clinical hold on RGX-121 due to MRI findings in trial participants. This regulatory setback is expected to delay the company's plans for resubmitting its Biologics License Application, creating uncertainty around the future of the therapy and impacting investor sentiment.